Comparison Centre
Two compounds, the same questions, no cherry-picking
Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.
Sharing keeps the two compounds you picked.
How to read these scores
Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.
- Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
- Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
- Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
- Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
- Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.
None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.
Goserelin
A GnRH agonist delivered as a small implant under the skin of the abdomen, suppressing sex hormones in prostate and breast cancer and certain gynaecological conditions.
Leuprolide
A GnRH agonist whose depot injections switch off sex-hormone production — used in prostate cancer, endometriosis and central precocious puberty depending on the product.
How far human research has progressed
Goserelin
Established hormone-suppression implantLeuprolide
Established hormone-suppression medicine familyClaim-specific benefit evidence
A human exposure study or trial registration does not establish that the claimed benefit occurs.
Goserelin
Not separately assessed; see the full profile.Leuprolide
Not separately assessed; see the full profile.Human research context
Goserelin
Established hormone-suppression implantLeuprolide
Established hormone-suppression medicine familyHuman efficacy evidence strength
Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
Goserelin
Leuprolide
Preclinical (animal / lab) evidence strength
Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
Goserelin
Leuprolide
Human safety evidence strength
Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.
Goserelin
Leuprolide
Regulatory status (legal position, not proof it works)
Goserelin
Named regulators: FDA (US)
FDA-approved (Zoladex) as a subcutaneous implant for indications including palliative treatment of advanced prostate cancer and certain breast-cancer and gynaecological uses, depending on product strength and label.
Leuprolide
Named regulators: FDA (US)
Multiple FDA-approved depot products exist with different indications — advanced prostate cancer, endometriosis, preoperative management of uterine fibroids and central precocious puberty among them. Each formulation and dosing interval is approved for specific uses.
Common claims
Goserelin
- · Suppresses sex-hormone production in hormone-sensitive cancers
- · Manages endometriosis and related gynaecological conditions
Leuprolide
- · Suppresses testosterone in advanced prostate cancer
- · Suppresses oestrogen in endometriosis
- · Pauses central precocious puberty
How settled our evidence rating is
Goserelin
Leuprolide
Cancer-related questions raised by the biology
These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.
Goserelin
Used as a treatment in hormone-sensitive cancers; no cancer-promotion signal within approved use.Leuprolide
Used deliberately as a treatment in hormone-sensitive prostate cancer; no cancer-promotion signal within approved use.What this adds up to, in plain English
Goserelin
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.Leuprolide
Repeated large human trials support specific uses in the groups studied. That is strong evidence something works there — not proof it suits everyone or is free of risk.A comparison is not a recommendation